Should Ercros, S.A. (BME:ECR) Be Part Of Your Dividend Portfolio?

Dividend paying stocks like Ercros, S.A. (BME:ECR) tend to be popular with investors, and for good reason - some research suggests a significant amount of all stock market returns come from reinvested dividends. Yet sometimes, investors buy a popular dividend stock because of its yield, and then lose money if the company's dividend doesn't live up to expectations.

Investors might not know much about Ercros's dividend prospects, even though it has been paying dividends for the last four years and offers a 2.7% yield. While the yield may not look too great, the relatively long payment history is interesting. During the year, the company also conducted a buyback equivalent to around 4.2% of its market capitalisation. When buying stocks for their dividends, you should always run through the checks below, to see if the dividend looks sustainable.

Click the interactive chart for our full dividend analysis

historic-dividend
BME:ECR Historic Dividend September 23rd 2020
Advertisement

Payout ratios

Dividends are typically paid from company earnings. If a company pays more in dividends than it earned, then the dividend might become unsustainable - hardly an ideal situation. Comparing dividend payments to a company's net profit after tax is a simple way of reality-checking whether a dividend is sustainable. In the last year, Ercros paid out 21% of its profit as dividends. Given the low payout ratio, it is hard to envision the dividend coming under threat, barring a catastrophe.

In addition to comparing dividends against profits, we should inspect whether the company generated enough cash to pay its dividend. Ercros paid out 15% of its free cash flow as dividends last year, which is conservative and suggests the dividend is sustainable. It's encouraging to see that the dividend is covered by both profit and cash flow. This generally suggests the dividend is sustainable, as long as earnings don't drop precipitously.

Remember, you can always get a snapshot of Ercros' latest financial position, by checking our visualisation of its financial health.

Dividend Volatility

From the perspective of an income investor who wants to earn dividends for many years, there is not much point buying a stock if its dividend is regularly cut or is not reliable. Ercros has been paying a dividend for the past four years. The dividend has not fluctuated much, but with a relatively short payment history, we can't be sure this is sustainable across a full market cycle. During the past four-year period, the first annual payment was €0.04 in 2016, compared to €0.05 last year. This works out to be a compound annual growth rate (CAGR) of approximately 5.7% a year over that time.

Ercros has been growing its dividend at a decent rate, and the payments have been stable despite the short payment history. This is a positive start.

Dividend Growth Potential

Dividend payments have been consistent over the past few years, but we should always check if earnings per share (EPS) are growing, as this will help maintain the purchasing power of the dividend. It's good to see Ercros has been growing its earnings per share at 16% a year over the past five years. Earnings per share are growing at a solid clip, and the payout ratio is low. We think this is an ideal combination in a dividend stock.

Conclusion

Dividend investors should always want to know if a) a company's dividends are affordable, b) if there is a track record of consistent payments, and c) if the dividend is capable of growing. It's great to see that Ercros is paying out a low percentage of its earnings and cash flow. Next, earnings growth has been good, but unfortunately the company has not been paying dividends as long as we'd like. Ercros performs highly under this analysis, although it falls slightly short of our exacting standards. At the right valuation, it could be a solid dividend prospect.

Companies possessing a stable dividend policy will likely enjoy greater investor interest than those suffering from a more inconsistent approach. Still, investors need to consider a host of other factors, apart from dividend payments, when analysing a company. For example, we've picked out 4 warning signs for Ercros that investors should know about before committing capital to this stock.

We have also put together a list of global stocks with a market capitalisation above $1bn and yielding more 3%.

If you’re looking to trade Ercros, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted


Valuation is complex, but we're here to simplify it.

Discover if Ercros might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020


Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

About BME:ECR

Ercros

Manufactures and sells basic chemicals, intermediate chemicals, and pharmaceuticals in Spain.

Reasonable growth potential and fair value.

Advertisement

Weekly Picks

ST
stuart_roberts
UNCY logo
stuart_roberts on Unicycive Therapeutics ·

Looking to be second time lucky with a game-changing new product

Fair Value:US$21.5370.8% undervalued
54 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
HE
PLY logo
HegelBayeBagel on PlaySide Studios ·

PlaySide Studios: Market Is Sleeping on a Potential 10M+ Unit Breakout Year, FY26 Could Be the Rerate of the Decade

Fair Value:AU$0.8460.7% undervalued
12 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
AN
AnimalDoctorKwon
NOTV logo
AnimalDoctorKwon on Inotiv ·

Inotiv NAMs Test Center

Fair Value:US$1.278.3% undervalued
19 users have followed this narrative
2 users have commented on this narrative
6 users have liked this narrative
TH
CGNT logo
TheValueDetector on Cognyte Software ·

This isn’t speculation — this is confirmation.A Schedule 13G was filed, not a 13D, meaning this is passive institutional capital, not acti

Fair Value:US$95.6792.9% undervalued
38 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative

Updated Narratives

UN
unknown
GS logo
unknown on Goldman Sachs Group ·

Goldman Sachs Group (GS) The Titan Reclaims Its Crown: Return to Core Excellence

Fair Value:US$1.06k12.7% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
UN
unknown
PH logo
unknown on Parker-Hannifin ·

Parker-Hannifin (PH) The Industrial Alchemist: Transforming Motion into Margin

Fair Value:US$1.12k8.4% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
UN
unknown
MPWR logo
unknown on Monolithic Power Systems ·

Monolithic Power Systems (MPWR) Powering the Hyperscale Era: The Efficiency Moat

Fair Value:US$1.35k10.7% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

DA
davidlsander
UBI logo
davidlsander on Ubisoft Entertainment ·

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share

Fair Value:€33.887.9% undervalued
61 users have followed this narrative
5 users have commented on this narrative
27 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$59633.4% undervalued
1292 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative
TA
Talos
TSLA logo
Talos on Tesla ·

The "Physical AI" Monopoly – A New Industrial Revolution

Fair Value:US$665.3638.1% undervalued
47 users have followed this narrative
19 users have commented on this narrative
22 users have liked this narrative

Trending Discussion

Advertisement